Relay Therapeutics, Inc. RLAY Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s cash & equivalents?
- Relay Therapeutics, Inc. (RLAY) reported cash & equivalents of $204.59M in Q1 2026.
- How has Relay Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Relay Therapeutics, Inc.'s cash & equivalents increased by 118.7% year-over-year, from $93.54M to $204.59M.
- What is the long-term trend for Relay Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s cash & equivalents has grown at a -28.4% compound annual growth rate (CAGR), from $447.65M to $84.02M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.